McDonald’s Corporation (MCD) beat analyst expectations for its second quarter 2018 results despite posting a 12% decrease in revenues. Consolidated revenues fell to $5.35 billion during the quarter, hurt by impacts from strategic re-franchising initiatives. Global comparable sales rose 4%, reflecting positive comp sales in all segments. Systemwide sales grew 5% in constant currencies.
Net income for the quarter rose 7% to $1.49 billion from the prior-year period. Diluted EPS improved 12% to $1.90, reflecting $0.09 per share of strategic restructuring charges. Adjusted diluted EPS grew 15% to $1.99 during the quarter. Earnings for the quarter benefited from an increase in sales-driven franchised margin dollars and a lower effective tax rate.
Sales at Company-owned restaurants fell 27% in the quarter while revenues from franchised restaurants increased 11%. The fast-food chain faced food poisoning issues during the quarter which led to a recall of salads at thousands of its restaurants across the nation.
In the US, comparable sales grew 2.6% driven by growth in average check resulting from product mix shifts and menu price increases. Comp sales in the International Lead segment rose 4.9%, reflecting positive results across all markets, mainly driven by the UK and France.
In the High Growth segment, comparable sales improved by 2.4%, led by strong performance in Italy and positive results across most of the segment. Comp sales in the Foundational markets rose 6.8%, reflecting positive sales performance across all geographic regions.
The company returned $2.5 billion to shareholders through share repurchases and dividends during the quarter.
Related: Lovin’ It: McDonald’s stock soars on upbeat first quarter
Related: McDonald’s Corp. Q2 2018 Earnings Call Transcript
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company